top of page
Dr. Siddharth Padia on the BackTable Tumor Board Podcast

Dr. Siddharth Padia

Interventional Radiologist

11 Podcasts • 18 Cases • 3 Courses on BackTable

Dr. Sid Padia is an interventional radiologist at UCLA in Los Angeles, California.

Learn from the experiences and expertise of Dr. Siddharth Padia and other leading voices in your specialty on the BackTable app.

How to Simplify Dosing: Understanding Y90 Dosimetry from Simple to Complex
00:00 / 01:04

Save your progress. Continue watching on the BackTable app.

BackTable Vascular & Interventional

Episode # 511  •  24 Jan 2025

How to Simplify Dosing: Understanding Y90 Dosimetry from Simple to Complex

Of all the topics covered during interventional radiology training, dosimetry education is often delayed until after IRs enter clinical practice. In this episode, Drs. Tyler Sandow and Sabeen Dhand host a roundtable discussion with experts on the dosimetry fundamentals that all Y90 operators should understand. They are joined by interventional radiologists Drs. Zachary Berman, Kirema Garcia-Reyes, and Siddharth Padia, who provide their expert insights.

This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific.

More from Dr. Siddharth Padia

Loading recent podcasts…

HCC: Super Challenging Case with Child-Pugh A Status

VI Case

Jan 24, 2025

HCC: Super Challenging Case with Child-Pugh A Status

HCC: Super Challenging Case with Child-Pugh A Status

HCC: Surgical & Non-Surgical Treatments for a 60-year Old with Solitary LR5

VI Case

Jan 22, 2025

HCC: Surgical & Non-Surgical Treatments for a 60-year Old with Solitary LR5

HCC: Surgical & Non-Surgical Treatments for a 60-year Old with Solitary LR5

HCC: 68-year Old Non-Cirrhotic Patient with an LR5 Lesion

VI Case

Jan 22, 2025

HCC: 68-year Old Non-Cirrhotic Patient with an LR5 Lesion

HCC: 68-year Old Non-Cirrhotic Patient with an LR5 Lesion

HCC: Multifocal Disease in a Non-Cirrhotic Patient

VI Case

Jan 22, 2025

HCC: Multifocal Disease in a Non-Cirrhotic Patient

HCC: Multifocal Disease in a Non-Cirrhotic Patient

HCC: Surgical & Non-Surgical Treatments for a 60-year Old with Solitary LR5

Tumor Board Case

Jan 22, 2025

HCC: Surgical & Non-Surgical Treatments for a 60-year Old with Solitary LR5

HCC: Surgical & Non-Surgical Treatments for a 60-year Old with Solitary LR5

HCC: 68-year Old Non-Cirrhotic Patient with an LR5 Lesion

Tumor Board Case

Jan 22, 2025

HCC: 68-year Old Non-Cirrhotic Patient with an LR5 Lesion

HCC: 68-year Old Non-Cirrhotic Patient with an LR5 Lesion

HCC: Multifocal Disease in a Non-Cirrhotic Patient

Tumor Board Case

Jan 22, 2025

HCC: Multifocal Disease in a Non-Cirrhotic Patient

HCC: Multifocal Disease in a Non-Cirrhotic Patient

HCC: 67-year Old with Cirrhosis, pHTN, 10cm Lesion

VI Case

Jan 22, 2025

HCC: 67-year Old with Cirrhosis, pHTN, 10cm Lesion

HCC: 67-year Old with Cirrhosis, pHTN, 10cm Lesion

Y90 Dosing & Ablation Modalities for HCC

Tumor Board Course

2 hours, 20 lessons

Genicular Artery Embolization

VI Course

3.5 hours, 27 lessons

IR, Surgical & Transplant Collaboration for HCC

Tumor Board Course

2 hours, 22 lessons

About

Dr. Siddharth Padia, MD is a specialist in vascular and interventional radiology at UCLA Medical Center. His areas of clinical expertise and research interests include liver cancer, interventional oncology, vascular disease and portal hypertension.

Dr. Padia earned his medical degree from Johns Hopkins University School of Medicine. After completing his transitional internship at The University of Hawaii in Honolulu, Dr. Padia began his residency in diagnostic radiology at the Cleveland Clinic in Ohio and graduated as Chief Resident. After spending many years practicing interventional radiology at the University of Washington, Dr. Padia joined the faculty at UCLA.

Dr. Padia specializes in a novel way to treat liver cancer by infusing highly radioactive particles (Yttrium-90) into the liver, and has treated over 800 patients with this therapy. He recently refined the technique by focusing higher doses to small amounts of tissue. These resulted in a success rate in excess of 90% of patients with liver cancer, and potentially surpasses other forms of treatment for patients with liver cancer. Due to his expertise in this field, he is the primary author of the national treatment guidelines for Yttrium 90 radioembolization, and is a director of the national annual course to educate physicians on this therapy.

Visit UCLA to learn more about Dr. Siddharth Padia.

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page